706 related articles for article (PubMed ID: 25917624)
1. Use of brodalumab for the treatment of psoriasis and psoriatic arthritis.
Kivelevitch DN; Menter A
Immunotherapy; 2015; 7(4):323-33. PubMed ID: 25917624
[TBL] [Abstract][Full Text] [Related]
2. The role of IL 23 in the treatment of psoriasis.
Puig L
Expert Rev Clin Immunol; 2017 Jun; 13(6):525-534. PubMed ID: 28165883
[TBL] [Abstract][Full Text] [Related]
3. Brodalumab -an IL-17RA monoclonal antibody for psoriasis and psoriatic arthritis.
Bauer E; Lucier J; Furst DE
Expert Opin Biol Ther; 2015 Jun; 15(6):883-93. PubMed ID: 25985813
[TBL] [Abstract][Full Text] [Related]
4. A review article on brodalumab in the treatment of moderate-to-severe plaque psoriasis.
Roostaeyan O; Kivelevitch D; Menter A
Immunotherapy; 2017 Sep; 9(12):963-978. PubMed ID: 28879789
[TBL] [Abstract][Full Text] [Related]
5. Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: Efficacy and safety results from a phase II randomized controlled study.
Nakagawa H; Niiro H; Ootaki K;
J Dermatol Sci; 2016 Jan; 81(1):44-52. PubMed ID: 26547109
[TBL] [Abstract][Full Text] [Related]
6. Ustekinumab: a review in the treatment of plaque psoriasis and psoriatic arthritis.
Zaghi D; Krueger GG; Callis Duffin K
J Drugs Dermatol; 2012 Feb; 11(2):160-7. PubMed ID: 22270196
[TBL] [Abstract][Full Text] [Related]
7. Brodalumab: the first anti-IL-17 receptor agent for psoriasis.
Puig L
Drugs Today (Barc); 2017 May; 53(5):283-297. PubMed ID: 28650001
[TBL] [Abstract][Full Text] [Related]
8. Interleukin 17-A inhibition in the treatment of psoriasis.
Yiu ZZ; Griffiths CE
Expert Rev Clin Immunol; 2016; 12(1):1-4. PubMed ID: 26561053
[TBL] [Abstract][Full Text] [Related]
9. IL-17 and IL-17R: an auspicious therapeutic target for psoriatic disease.
Mitra A; Raychaudhuri SK; Raychaudhuri SP
Actas Dermosifiliogr; 2014 Oct; 105 Suppl 1():21-33. PubMed ID: 25398489
[TBL] [Abstract][Full Text] [Related]
10. Pathogenic role of IL-17 in psoriasis and psoriatic arthritis.
Chiricozzi A
Actas Dermosifiliogr; 2014 Oct; 105 Suppl 1():9-20. PubMed ID: 25398488
[TBL] [Abstract][Full Text] [Related]
11. Role of IL-17 in psoriasis and psoriatic arthritis.
Raychaudhuri SP
Clin Rev Allergy Immunol; 2013 Apr; 44(2):183-93. PubMed ID: 22362575
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis.
Mease PJ
Curr Opin Rheumatol; 2015 Mar; 27(2):127-33. PubMed ID: 25599143
[TBL] [Abstract][Full Text] [Related]
13. Cytokine-based therapy in psoriasis.
Mitra A; Fallen RS; Lima HC
Clin Rev Allergy Immunol; 2013 Apr; 44(2):173-82. PubMed ID: 22426927
[TBL] [Abstract][Full Text] [Related]
14. [Monoclonal antibodies targeting IL-17A or its receptor in psoriasis: a new therapeutic approach?].
Bonnet MC; Bagot M; Bensussan A
Med Sci (Paris); 2012 Dec; 28(12):1035-7. PubMed ID: 23290394
[No Abstract] [Full Text] [Related]
15. The Role of IL-17 in the Pathogenesis of Psoriasis and Update on IL-17 Inhibitors for the Treatment of Plaque Psoriasis.
AbuHilal M; Walsh S; Shear N
J Cutan Med Surg; 2016 Nov; 20(6):509-516. PubMed ID: 27207350
[TBL] [Abstract][Full Text] [Related]
16. The role of IL-17 in the treatment of psoriatic arthritis.
Lubrano E; Perrotta FM
Expert Rev Clin Immunol; 2017 Aug; 13(8):815-821. PubMed ID: 28485176
[TBL] [Abstract][Full Text] [Related]
17. Brodalumab for the treatment of psoriasis.
Galluzzo M; D'adamio S; Bianchi L; Talamonti M
Expert Rev Clin Immunol; 2016 Dec; 12(12):1255-1271. PubMed ID: 27718760
[TBL] [Abstract][Full Text] [Related]
18. Prospective new biologic therapies for psoriasis and psoriatic arthritis.
Mortel MR; Emer J
J Drugs Dermatol; 2010 Aug; 9(8):947-58. PubMed ID: 20684145
[TBL] [Abstract][Full Text] [Related]
19. Rationale and early clinical data on IL-17 blockade in psoriasis.
Nwe SM; Champlain AH; Gordon KB
Expert Rev Clin Immunol; 2013 Jul; 9(7):677-82. PubMed ID: 23899238
[TBL] [Abstract][Full Text] [Related]
20. Effect of IL-17 receptor A blockade with brodalumab in inflammatory diseases.
Nirula A; Nilsen J; Klekotka P; Kricorian G; Erondu N; Towne JE; Russell CB; Martin DA; Budelsky AL
Rheumatology (Oxford); 2016 Dec; 55(suppl 2):ii43-ii55. PubMed ID: 27856660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
